Literature DB >> 25905908

Prediction of CD8+ Epitopes in Leishmania braziliensis Proteins Using EPIBOT: In Silico Search and In Vivo Validation.

Angelo Duarte1, Artur T L Queiroz2, Rafael Tosta1, Augusto M Carvalho2, Carlos Henrique Barbosa3, Maria Bellio3, Camila I de Oliveira4, Manoel Barral-Netto4.   

Abstract

BACKGROUND: Leishmaniasis is caused by intracellular Leishmania parasites that induce a T-cell mediated response associated with recognition of CD4+ and CD8+ T cell Line 1Lineepitopes. Identification of CD8+ antigenic determinants is crucial for vaccine and therapy development. Herein, we developed an open-source software dedicated to search and compile data obtained from currently available on line prediction algorithms. METHODOLOGY/PRINCIPAL
FINDINGS: We developed a two-phase algorithm and implemented in an open source software called EPIBOT, that consolidates the results obtained with single prediction algorithms, generating a final output in which epitopes are ranked. EPIBOT was initially trained using a set of 831 known epitopes from 397 proteins from IEDB. We then screened 63 Leishmania braziliensis vaccine candidates with the EPIBOT trained tool to search for CD8+ T cell epitopes. A proof-of-concept experiment was conducted with the top eight CD8+ epitopes, elected by EPIBOT. To do this, the elected peptides were synthesized and validated for their in vivo cytotoxicity. Among the tested epitopes, three were able to induce lysis of pulsed-target cells.
CONCLUSION: Our results show that EPIBOT can successfully search across existing prediction tools, generating a compiled list of candidate CD8+ epitopes. This software is fast and a simple search engine that can be customized to search over different MHC alleles or HLA haplotypes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25905908      PMCID: PMC4407964          DOI: 10.1371/journal.pone.0124786

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Leishmaniasis is an infectious disease with significant economic impact in several countries. Over three hundred million people are exposed to the parasites, with 12 million infected worldwide, predominantly in tropical and subtropical countries (World Health Organization page: http://www.who.int/emc/diseases/leish/leisdis1.html). Leishmaniasis can be caused by different species of Leishmania spp. protozoans that infect macrophages in the human host. The treatments available for all forms of leishmaniasis are toxic and drug resistance is on the rise, further increasing the need for vaccine development [1]. In Brazil, cutaneous leishmaniasis (CL) is caused mostly by Leishmania braziliensis and presents as a skin ulcer associated with an intense inflammatory reaction with the presence of T cells [2]. The main immune mechanism for the control of Leishmania infection is IFN-γ production and subsequent macrophage activation, enabling the elimination of intracellular Leishmania parasites. It has been shown that CD4+ T cells are the main source of IFN- γ production, and, hence, macrophage activation (rev. in [3]). CD8+ T cells, on the other hand, are cytotoxic and contribute with pathogenesis of CL caused by L. braziliensis: CD8+ T cells promote lysis of leishmania-infected cells [4,5]. Moreover, the frequency of CD8+ T cells expressing cytotoxic mediators such as granzyme is directly correlated with the intensity of inflammatory reaction CL lesions [6]. The activation of CD8+ T cells is dependent on the recognition of antigenic peptide, presented by major histocompatibility complex molecules at the surface of infected cells [7]. Given the association of CD8+ T cell with pathogenesis of CL, it has become important to identify putative L. braziliensis CD8+ peptides associated with the cytotoxic response. Experimental identification of MHC-binding peptides requires an assay for each peptide, a time consuming and costly process [8]. In silico epitope and MHC-peptide binding prediction, on the other hand, allow optimization of epitope discovery in vaccine design studies, therefore reducing the experimental workload [9]. A variety of algorithms have been developed and used in the field of epitope prediction and these algorithms range from Simplest Sequence Motifs and position-specific scoring matrices (PSSM) [10] to more complex machine-learning probabilistic approaches, such as Hidden Markov Models (HMM) [11], Artificial Neural Networks (ANN) [12] and Support Vector Machines (SVM) [13]. However, epitope discovery using distinct algorithms results in contrasting outputs, rendering candidate selection a cumbersome task. Since epitope mapping is important for the screening of cellular immunity in protected individuals, for example, an algorithm than combines different search methodologies and generates a unique list of candidates becomes a useful tool. Here, we developed a two-phase algorithm that merges the results generated by individual prediction algorithms generating a unified final rank of elected epitopes. The algorithm was implemented in EPIBOT, a free software for non-commercial use developed in JAVA language. The zip source is available at: https://sites.google.com/a/ecomp.uefs.br/angeloduarte/epibot?pli=1. To run the friendly-interface, the user needs to extract the EPIBOT.rar file and navigate to folder. To execute in Windows and Mac OS, user double clicks the. jar file. For Linux OS execute the shell command java—jar Epibot.jar. More information is available in the software manual. EPIBOT was tested with 63 Leishmania braziliensis proteins and the top predicted eight epitopes were validated in vivo for their potential to induce CD8+ T cell cytotoxicity.

Materials and Methods

Software development

EPIBOT callibration and training. To measure the accuracy of the prediction tools (netMHC, SYFPEITHII, BIMAS, SVMHC and IEDB), we initially provided EPIBOT with a dataset of proteins containing known CD8+ epitopes: we used a set of 4251 H2-Kd epitopes, available in IEDB. However, among these only 831 proteins (S1 Table) with CD8+ epitopes were recovered from NCBI. Entries without reports at duplicates and proteins with more than 1 epitope were also removed from the dataset leaving 397 proteins (S2 Table) with identified CD8+ epitopes. These were used to assess the accuracy of the different prediction algorithms. Each calibration protein was then individually submitted to the following epitope prediction algorithm: BIMAS [14], SYFPEITHII [10], netMHC [15], SVMHC [16] and IEDB In every case, we searched for peptides presenting high affinity with mouse MHC class I molecules of BALB/c mice (H2- Kd). Each search resulted in an epitope rank, where the best ranked epitope is expected to present a top score (rank = 1). This list was ordered according to the peptide score and the top epitopes ranked equal or close to 1. Therefore, each epitope rank (its compiled list position) is the algorithm´s prediction quality indicator. A perfect algorithm would classify known CD8 epitopes at the top. Thus, a Specific Prediction Score (SPS) was defined: this scores the algorithm’s quality for a specific calibration protein (and its calibration epitope). The SPS is the inverse of the Rank of the Calibration Epitope (RCE), from the list of epitopes yielded by the algorithm, presented in Eq 1: To assess overall algorithm quality, a General Prediction Score (GPS) was determined for each prediction algorithm, using all proteins SPS averages measured from the calibration set (defined in Eq 2). The Number of Calibration Proteins (NCP) was applied. The factor 10 was used to normalize GPS range to 0–10 interval. Good prediction algorithms are expected to have a GPS near 10.SPS After calibration phase, the software determines the GPS value for each prediction algorithm. Thus, the EPIBOT algorithm is trained and ready to perform epitope screening in the query protein set.

EPIBOT Unified prediction

After EPIBOT calibration, the GPS values are used to predict epitopes in a query dataset. Thereby, the two-step consolidation algorithm submits each query protein individually to the prediction algorithms (netMHC, SYFPEITHII, BIMAS, SVMHC and IEDB) and then measures the Unified Epitope Score (UES). First, the epitope-predicted list generated by each algorithm was normalized, where normalized scores (NS) range from [0-1] where 1 is the top epitope score and 0 is the bottom epitope score. Second, for a given Number of Prediction Algorithms (NPA), the UES is calculated using Eq 3, by summing epitope normalized scores, from each prediction algorithm, multiplied by the general prediction score from each different algorithm. The final EPIBOT output is an epitope-predicted list descending by UES order, based on prediction from a prediction algorithm set defined by the user. Thus, the top epitopes are the best potential epitopes.

EPIBOT prediction using L. braziliensis query proteins

Sixty-three Leishmania braziliensis proteins were screened with EPIBOT for the discovery of potential 9-mer epitopes presented by H2-Kd (Table 1). These epitopes were then validated in vivo, using a cytotoxicity assay, as described below. The full sequences of the proteins were extracted from NCBI. The selected proteins have been previously defined as candidate antigens [17-20] and were tested with the trained EPIBOT algorithm, using the five prediction tools mentioned above. The prediction output was evaluated and sorted by UES. The top epitopes were compared to mouse proteins using BLAST [11].Epitopes with query coverage of 100% and identity superior to 90% with self-murine proteins from ref_seq database were discarded. The predicted peptides were also compared to known epitopes from IEDB database to avoid known-epitopes re-evaluation.
Table 1

L. braziliensis protein query set.

Accession NumberDescriptionAccession NumberDescription
XP001562139cathepsin L-like proteaseXP001562925GP63, leishmanolysin
XP001562140cathepsin L-like proteaseXP001562927GP63, leishmanolysin
XP001562141cathepsin L-like proteaseXP001562928GP63, leishmanolysin
XP001562145stress-induced protein sti1XP001562929GP63, leishmanolysin
XP001562173histone H4XP001562930GP63, leishmanolysin
XP001562184histone H4XP001562931GP63, leishmanolysin
XP001562231histone H4XP001562932GP63, leishmanolysin
XP001568634histone H4XP001562933GP63, leishmanolysin
XP001561520histone H4XP001562934GP63, leishmanolysin
XP001562231histone H4XP001562935GP63, leishmanolysin
XP001562753histone H2BXP001562936GP63, leishmanolysin
XP001562816GP63, leishmanolysinXP001562937GP63, leishmanolysin
XP001562817GP63, leishmanolysinXP001562938GP63, leishmanolysin
XP001562818GP63, leishmanolysinXP001563556tryparedoxin peroxidase
XP001562819GP63, leishmanolysinXP001563966UDP-galactose transporter
XP001562820GP63, leishmanolysinXP001564130histone H2B
XP001562821GP63, leishmanolysinXP001564131histone H2B
XP001562822GP63, leishmanolysinXP001564132histone H2B
XP001562823GP63, leishmanolysinXP001564191putative histone H3 variant
XP001562824GP63, leishmanolysinXP001564262cysteine peptidase A (CPA)
XP001562825GP63, leishmanolysinXP001564551lipophosphoglycan biosynthetic protein (lpg2)
XP001562826GP63, leishmanolysinXP001564819histone H2A
XP001562827GP63, leishmanolysinXP001565254histone H4
XP001562827GP63, leishmanolysinXP001566056histone H2B variant
XP001562828GP63, leishmanolysinXP001566321activated protein kinase c receptor (LACK)
XP001562829GP63, leishmanolysinXP001566431cysteine peptidase C (CPC)
XP001562830GP63, leishmanolysinXP001567803heat shock protein 83–1
XP001562865histone H3XP001567804heat shock protein 83–1
XP001562920GP63, leishmanolysinXP001568323kinetoplastid membrane protein-11
XP001562921GP63, leishmanolysinXP001568634histone H4
XP001562923GP63, leishmanolysin

In vivo validation of predicted epitopes

Ethics Statement

Female BALB/c mice, 6–8 weeks of age, 25–30 grams, were obtained from CPqGM/FIOCRUZ animal facility where they were maintained under pathogen-free conditions. Mice were housed in groups of five. Environmental conditions were a temperature of 21°C ±2°, humidity of 55% ±10%, and a 12:12 light:dark cycle with lights on at 0700 and off at 1900. Animals were housed in 422×230×203 mm cages (Domi Series, Alesco, Brazil) and given access to mouse maintenance food (Biobase Bio Tec, Brazil) and water ad libitum. Environmental enrichment included bedding (maravalha Pinus elliotti, Hemo In Produtos para Biotério, Brazil), one red tinted igloo (Alesco, Brazil). During housing, animals were monitored twice daily for health status. No adverse events were observed. In vivo validation was performed using 36 animals. Splenocytes to be pulsed with peptides were obtained from 12 naive mice. Pulsed and labeled splenocytes were injected into 24 L. braziliensis-infected mice. All animal work was conducted according to the Guidelines for Animal Experimentation of the Colégio Brasileiro de Experimentação Animal and of the Conselho Nacional de Controle de Experimentação Animal. The local Ethics Committee on Animal Care and Utilization (CEUA) approved all procedures involving animals (L-03/2011). All sections of this report adhere to the ARRIVE Guidelines for reporting animal research. A completed ARRIVE guidelines checklist is included in S1 ARRIVE Checklist. To obtain splenocytes and draining lymph node cells, mice were euthanized using compressed CO2 under a flow rate of 1–3 liters per minute for a 10 liter (volume) chamber. CO2 flow was maintained for a minimum of 1 minute until lack of respiration and faded eye color were observed.

Parasite culture, intradermal inoculation and lesion measurement

L. braziliensis promastigotes strain MHOM/BR/01/BA788 were grown in Schneider medium (Sigma) supplemented with 100U/ml of penicillin, 100ug/ml of streptomycin, 10% heat-inactivated fetal calf serum (all from Life Technologies). Stationary-phase promastigotes (105 parasites in 10μl of saline) were inoculated into the right ear dermis of age-matched BALB/c mice using a 27.5-gauge needle. Lesion size was monitored weekly, for 5 weeks, using a digital calliper (Thomas Scientific).

In vivo cytotoxicity assay

Splenocytes were obtained from naive BALB/c (H2-Kd). Cells were divided into three groups and were labeled with the fluorogenic dye CFDA (Invitrogen) at final concentrations of 8 μM (CFDAhigh), 2 μM (CFDAintermediate) or 0.5 μM (CFDAlow). CFDAhigh cells were previously pulsed for 40 minutes at 37°C with 5 μM of H-2Kd-restricted L. braziliensis peptides (AYLASCDFI, AYIDGHVTI, KYQHSTEML or TYQRVYATL. CFDAintermediate cells were pulsed in the same way with WYLATHSLI, SYMGYFQNI, IYVSYADLI or VYLSFGFRL). CFDAlow cells remained unpulsed. Subsequently, CFDAhigh and CFDAintermediate cells were washed and mixed with equal numbers of CFDAlow cells before injecting intravenously (15–20 x 106 total cells) into L. braziliensis-infected and into control non-infected mice. Draining lymph node and spleen cells of recipient mice were collected 20 hours after cell transfer, fixed and analyzed by cytometry, using a FACSCalibur Cytometer (BD Biosciences). Percentage of CFDAlow (M1), CFDAintermediate (M2) and CFDAhigh (M3) cells were obtained using CellQuest software (BD Biosciences). Percentage of specific lysis was determined using the formula: 1 –((M2 infected/M1 infected) / (M2 naïve/ M1 naïve)) x 100% or 1 –((M3 infected/M1 infected) / (M3 naïve/ M1 naïve)) x 100% [21].

Statistical analysis

A non-parametrical Mann Whitney U test was used to evaluate the difference between groups. Pvalue less than 0.05 have been considered significant.

Results

In silico analysis of L. braziliensis proteins for potential candidate peptides

To identify potential CD8+ T cell activating 9-mer epitopes presented by H2-Kd we used the trained EPIBOT on a query dataset of 63 L. braziliensis protein candidates (Table 1). EPIBOT screening generated an output of 10950 UES-associated epitopes. The output list was sorted and the eight best-predicted epitopes with UES above 9.5 (Table 2) were chosen: AYLASCDFI, WYLATHSLI, AYIDGHVTI, SYMGYFQNI, GYVGIVVAL, KYQHSTEML, IYVSYADLI, VYLSFGFRL. These peptides were synthesized and validated in vivo.
Table 2

Top L. braziliensis epitopes as predicted by EPIBOT.

EPITOPEUES a AccessionDescription% Lysis (mean of spleen and dLN values)
AYLASCDFI13.296XP001562821GP63 leishmanolysin5.75
AYLASCDFL13.193XP001562826GP63 leishmanolysinNT b
AYLATCDFL13.003XP001562925GP63 leishmanolysinNT
WYLATHSLI12.534XP001562139cathepsin L-like protease(CPB)44.88
AYIDGHVTI12.063XP001562141cathepsin L-like protease(CPB)43.82
SYMGYFQNI11.183XP001564262cysteine peptidase A (CPA)8.28
GYVGIVVAL10.56XP001564551lipophosphoglycan biosynthetic protein (lpg2)NT
KYQHSTEML10.505XP001564191histone H3 variant12.02
IYVSYADLI9.979XP001562817GP63 leishmanolysin54.17
TYQRVYATL9.947XP001562141cathepsin L-like protease(CPB)7.15
VYLSFGFRL9.601XP001562184histone H49.91

aUES, Unified Epitope Score

bNT: not tested

aUES, Unified Epitope Score bNT: not tested

In vivo cytotoxicity following inoculation of peptide-pulsed splenocytes into L. braziliensis-infected mice

Following epitope prediction using EpiBot, we validated the top eight peptides in vivo, using an assay that measures cytotoxicity of CD8+ T cells following an encounter with peptide-pulsed cells. No expressive cytotoxicity activity was observed when cells were pulsed with AYLATCDFI or SYMGYFQNI peptides (Fig 1A). On the other hand, the percentage of specific lysis of cells pulsed with WYLATHSLI was 42.2% in the spleen and 47.6% in the draining lymph node, while specific lysis for cells pulsed with AYIDGHVTI was 35.5%, in the spleen and and 52.1% % in the draining lymph node. Among the other four peptides tested, specific lysis was found only for peptide IYVSYADLI which displayed 52% and 56% of specif lysis in the spleen and draining lymph nodes, respectively (Fig 1B).
Fig 1

Specific CD8+ T cell-mediated immune response in L. braziliensis-infected BALB/c mice.

Target cells were pulsed with L. braziliensis peptides (A) AYLASCDFI, WYLATHSLI, AYIDGHVTI and SYMGYFQNI and (B) GYVGIVVAL, KYQHSTEML, IYVSYADLY and VYLSFGFRL. Target cells were then transferred to L. braziliensis infected mice. In vivo cytoxoxicity was analyzed in spleen (white squares) and in draining lymph nodes (red squares) of recipient mice, by flow cytometry, as described in Materials and Methods. Data are shown individually.

Specific CD8+ T cell-mediated immune response in L. braziliensis-infected BALB/c mice.

Target cells were pulsed with L. braziliensis peptides (A) AYLASCDFI, WYLATHSLI, AYIDGHVTI and SYMGYFQNI and (B) GYVGIVVAL, KYQHSTEML, IYVSYADLY and VYLSFGFRL. Target cells were then transferred to L. braziliensis infected mice. In vivo cytoxoxicity was analyzed in spleen (white squares) and in draining lymph nodes (red squares) of recipient mice, by flow cytometry, as described in Materials and Methods. Data are shown individually.

Discussion

The identification of MHC-associated epitopes, recognized by T cells, is essential to measure epitope-specific T cell responses. Several approaches have been developed to improve epitope discovery (rev. in [9]), however, the variability observed among existing prediction tools rises important questions concerning the approaches´ consensus. Herein, we developed an analysis tool, EPIBOT, capable of epitope prediction across different prediction algorithms currently available online. EPIBOT was tested on query set of 63 L. braziliensis and the top eight epitopes were synthesized for in vivo validation. Although the use of EPIBOT on 63 proteins from the L. braziliensis proteome yielded a large number of predicted epitopes, such result was lower than that obtained using different prediction tool (BIMAS, SYFPEITHII, netMHC, SVMHC and IEDB) individually. After calibration, EPIBOT automatically submits each protein to the prediction tools selected by the user and all outputs are stored in an SQL database. The user only defines the protein queries set in a single initial submission. This solves all multi-submissions and high throughput issues. These features allow the user to test different prediction tools in large queries, containing many different proteins, thereby improving epitope search. In this way, EPIBOT handles large data sets, generated following the search by each predictor, combining different methodologies together with a rational output, yielding a unified score. EPIBOT was able to handle the data groups generated by each predictor, combining different methodologies together with a rational output and generating a unique predictor score. The approach of combining results from several prediction tools is advantageous since integration of many prediction methods improves the overall prediction performance [22]. Additionally, this helps solving a crucial issue regarding different epitope prediction algorithms: the different score metrics used by each algorithm. For example, BIMAS [14] uses HLA class I half time dissociation, while SYFPEITHI [10] uses log-based score. Moreover, EPIBOT enables the use of different predictors tools in a set of proteins, generating a predicted epitopes pool, allowing epitope comparison based on a single score. This poses advantages over the use of a single prediction algorithm at a time so that the user can submit a query dataset at once instead of submitting each protein to each algorithm, one at a time. Besides, EPIBOT generates a simpler rational output in which the resulting epitopes are already ranked. Lastly, we compared the output of EPIBOT with that of some existing algorithms, using the same set of proteins tested in two published studies: Seyed et al. [23] described the results of in-silico prediction for six L. major proteins and indicated 18 epitopes for the HLA-0201 allele. Using the same set of proteins, EPIBOT identified 10 of the 18 epitopes in the top 10 positions (of the output list) and 15 of the 18 epitopes in the top 19 positions (of the output list). Agallou et al. [24] evaluated four leishmania proteins: 18 epitopes were predicted by SYFPEITHI and 24 epitopes predicted Bimas for the H2-Kd allele. Bimas did not predict certain epitopes predicted by SYFPEITHI and vice-versa; only 12 epitopes were predicted by both algorithms. Using this same set of proteins, EPIBOT yielded a result list in which seven of these 12 epitopes were in the top 10 positions, one epitope was in the 59th position and the remaining four epitopes above the position 200. These results confirmed that EPIBOT performs well and is capable of combining the results of different prediction sites, yielding a more robust and meaningful prediction. Another crucial issue generally observed across epitope prediction tools is the setting of output threshold. The choice of the threshold remains unclear and it is generally decided upon by the user: in one work, authors chose 20 as the threshold score for SYFPEITHI and 100 for BIMAS for the identification of L. major epitopes [23]. Elsewhere, the output threshold was defined by the top 5 highest scoring epitopes, among multiple predictors used [25]. Threshold cut-offs were also applied for epitope discovery in L. infantum. However, a score ≥18 for SYFPEITHI and binding affinity <500 nM for NetMCH were used for merging queries´ search [24]. EPIBOT, on the other hand, executes a rational comparison of the outputs from several prediction tools, which employ different prediction metrics. Using EPIBOT with a query set of 63 L. braziliensis proteins, the software identified 10,950 L. braziliensis peptides. We then opted to validate the top eight predicted epitopes, in vivo as targets for CD8+ T cells. In T. cruzi infection, a similar assay detected >90% specific lyses in infected mice when cells were pulsed with the T. cruzi peptide VNHRFTLV [26]. The epitopes validated in vivo derived from L. braziliensis cathepsin L-like protein and Histone H3 [27]. Different studies showed that CD8+ T cells contribute with immunity to leishmania [28-31]. In the case of L. braziliensis infection, however, mice depleted of CD8+ T cells develop smaller lesions when compared with mice treated with isotype control antibody [5]. In addition, transfer of CD8+ T cells to Rag–/– mice, that lack T cells, infected with L. braziliensis results in the development of uncontrolled and metastatic lesions. Nonetheless, CD8+ T cells producing IFN-γ are also detected in L. braziliensis-infected mice [32], indicating that these cells can contribute with macrophage activation and parasite elimination. Therefore, EPIBOT will contribute towards the identification of CD8 epitopes, enabling a better understanding of the role of CD8 cells during leishmania infection. Of note, comparing EPIBOT, BIMAS, SYFPEITHII, IEDB, NetMHC and SVMHC, only BIMAS was able to identify, among the 63 L. braziliensis proteins, the same three epitopes we herein validated in vivo. The other predictors, when used alone, identified either one or two epitopes only (data not shown). Our results are in line with reports in the literature indicating the feasibility of using in silico predictors to identify CD8+ epitopes within Leishmania proteins [23,25]. However, we demonstrate that a combined approach such as EPIBOT accelerates epitope discovery in the sense that predictions are compiled from different algorithms. Indeed, among the eight epitopes tested, three induced cytotoxic activity in vivo, validating our search mechanism. Importantly, it was recently shown that the combination of epitope predictors, such as B cells predictors, yielded better results with protozoan parasite proteins [33]. (DOCX) Click here for additional data file.

List of previously described CD8+ IEDB epitopes used to train EPIBOT.

(DOCX) Click here for additional data file.

List of proteins with known CD8+ epitopes used to train EPIBOT.

(DOCX) Click here for additional data file.
  32 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Tatiana R de Moura; Fernanda O Novais; Fabiano Oliveira; Jorge Clarêncio; Almério Noronha; Aldina Barral; Claudia Brodskyn; Camila I de Oliveira
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Harnessing bioinformatics to discover new vaccines.

Authors:  Matthew N Davies; Darren R Flower
Journal:  Drug Discov Today       Date:  2007-04-06       Impact factor: 7.851

4.  Clinical characteristics of human Leishmania braziliensis braziliensis infections.

Authors:  E A Llanos Cuentas; C C Cuba; A C Barreto; P D Marsden
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

5.  An in silico immunological approach for prediction of CD8+ T cell epitopes of Leishmania major proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection.

Authors:  F Z Guerfali; H Ben-Abdallah; R M Sghaier; K Ben-Aissa; G Mkannez; H Attia; D Laouini
Journal:  Infect Genet Evol       Date:  2008-03-04       Impact factor: 3.342

6.  Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.

Authors:  G Salay; M L Dorta; N M Santos; R A Mortara; C Brodskyn; C I Oliveira; C L Barbiéri; M M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2007-07-11

7.  SVMHC: a server for prediction of MHC-binding peptides.

Authors:  Pierre Dönnes; Oliver Kohlbacher
Journal:  Nucleic Acids Res       Date:  2006-07-01       Impact factor: 16.971

8.  The immune epitope database 2.0.

Authors:  Randi Vita; Laura Zarebski; Jason A Greenbaum; Hussein Emami; Ilka Hoof; Nima Salimi; Rohini Damle; Alessandro Sette; Bjoern Peters
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971

9.  Comparative genomic analysis of three Leishmania species that cause diverse human disease.

Authors:  Christopher S Peacock; Kathy Seeger; David Harris; Lee Murphy; Jeronimo C Ruiz; Michael A Quail; Nick Peters; Ellen Adlem; Adrian Tivey; Martin Aslett; Arnaud Kerhornou; Alasdair Ivens; Audrey Fraser; Marie-Adele Rajandream; Tim Carver; Halina Norbertczak; Tracey Chillingworth; Zahra Hance; Kay Jagels; Sharon Moule; Doug Ormond; Simon Rutter; Rob Squares; Sally Whitehead; Ester Rabbinowitsch; Claire Arrowsmith; Brian White; Scott Thurston; Frédéric Bringaud; Sandra L Baldauf; Adam Faulconbridge; Daniel Jeffares; Daniel P Depledge; Samuel O Oyola; James D Hilley; Loislene O Brito; Luiz R O Tosi; Barclay Barrell; Angela K Cruz; Jeremy C Mottram; Deborah F Smith; Matthew Berriman
Journal:  Nat Genet       Date:  2007-06-17       Impact factor: 38.330

10.  Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis.

Authors:  Fernanda O Novais; Lucas P Carvalho; Joel W Graff; Daniel P Beiting; Gordon Ruthel; David S Roos; Michael R Betts; Michael H Goldschmidt; Mary E Wilson; Camila I de Oliveira; Phillip Scott
Journal:  PLoS Pathog       Date:  2013-07-18       Impact factor: 6.823

View more
  8 in total

1.  Correction: Prediction of CD8+ Epitopes in Leishmania braziliensis Proteins Using EPIBOT: In Silico Search and In Vivo Validation.

Authors:  Angelo Duarte; Artur T L Queiroz; Rafael Tosta; Augusto M Carvalho; Carlos Henrique Barbosa; Maria Bellio; Camila I de Oliveira; Manoel Barral-Netto
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

2.  Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.

Authors:  Micheli Luize Barbosa Santos; Dirlei Nico; Fabrícia Alvisi de Oliveira; Aline Silva Barreto; Iam Palatnik-de-Sousa; Eugenia Carrillo; Javier Moreno; Paula Mello de Luca; Alexandre Morrot; Daniela Santoro Rosa; Marcos Palatnik; Cristiane Bani-Corrêa; Roque Pacheco de Almeida; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-03-07       Impact factor: 7.561

3.  Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies.

Authors:  Rory C F Brito; Frederico G Guimarães; João P L Velloso; Rodrigo Corrêa-Oliveira; Jeronimo C Ruiz; Alexandre B Reis; Daniela M Resende
Journal:  Int J Mol Sci       Date:  2017-02-10       Impact factor: 5.923

4.  Synthetic Peptides as Potential Antigens for Cutaneous Leishmaniosis Diagnosis.

Authors:  Juliana Seger Link; Silvana Maria Alban; Carlos Ricardo Soccol; Gilberto Vinicius Melo Pereira; Vanete Thomaz Soccol
Journal:  J Immunol Res       Date:  2017-03-07       Impact factor: 4.818

5.  In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein.

Authors:  Nabarun Chandra Das; Pritha Chakraborty; Jagadeesh Bayry; Suprabhat Mukherjee
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

6.  Combination of In Silico Methods in the Search for Potential CD4(+) and CD8(+) T Cell Epitopes in the Proteome of Leishmania braziliensis.

Authors:  Rafael de Freitas E Silva; Luiz Felipe Gomes Rebello Ferreira; Marcelo Zaldini Hernandes; Maria Edileuza Felinto de Brito; Beatriz Coutinho de Oliveira; Ailton Alvaro da Silva; Osvaldo Pompílio de-Melo-Neto; Antônio Mauro Rezende; Valéria Rêgo Alves Pereira
Journal:  Front Immunol       Date:  2016-08-29       Impact factor: 7.561

7.  pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.

Authors:  Jasreet Hundal; Beatriz M Carreno; Allegra A Petti; Gerald P Linette; Obi L Griffith; Elaine R Mardis; Malachi Griffith
Journal:  Genome Med       Date:  2016-01-29       Impact factor: 11.117

Review 8.  Peptide Vaccines for Leishmaniasis.

Authors:  Rory C F De Brito; Jamille M De O Cardoso; Levi E S Reis; Joao F Vieira; Fernando A S Mathias; Bruno M Roatt; Rodrigo Dian D O Aguiar-Soares; Jeronimo C Ruiz; Daniela de M Resende; Alexandre B Reis
Journal:  Front Immunol       Date:  2018-05-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.